Research programme: BRAF inhibitors - Astex/Wellcome Trust/ICR

Drug Profile

Research programme: BRAF inhibitors - Astex/Wellcome Trust/ICR

Alternative Names: BRAF inhibitors research programme - Astex/Wellcome Trust/ICR

Latest Information Update: 06 Oct 2011

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator The Wellcome Trust
  • Developer Astex Therapeutics; Cancer Research Technology; The Institute of Cancer Research; The Wellcome Trust
  • Class
  • Mechanism of Action Genetic transcription inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 20 Jul 2011 Astex Therapeutics has been acquired by SuperGen
  • 26 Mar 2004 Preclinical trials in Cancer in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top